# ClinicalTrials.gov record NCT06554717

> PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct06554717-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06554717-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06554717-tesamorelin-v1.json
- Content SHA-256: `4e657d41c68d44f2a4c3ad73ec13e1bc8bcf0db5dd59ee7b7d4359335e84bb6d`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT06554717 ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

## Sources

<a id="source-ctg-observation-nct06554717-2026-05-19-778551eac8ae"></a>
- **ClinicalTrials.gov record NCT06554717 · retained source version 2026-05-19:778551eac8ae5487f8e1cbd2d1ffa5adb07326643d805b8f6a7f79c90b905b2a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06554717) (`ctg-observation-nct06554717-2026-05-19-778551eac8ae`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06554717." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct06554717-tesamorelin-v1.json SHA-256: 4e657d41c68d44f2a4c3ad73ec13e1bc8bcf0db5dd59ee7b7d4359335e84bb6d.